OBJECTIVE

To evaluate the economic feasibility of expanding the use of netakimab for the treatment of adult patients with moderate to severe psoriasis vulgaris compared to other biologics and small molecules used in the health care settings of the Russian Federation.

MATERIAL AND METHODS

Costs were calculated according to the dosing regimen approved in the Russian Federation for all considered treatment options for adults with moderate to severe psoriasis vulgaris. The analysis used the registered prices inlcuding VAT of the manufacturer, including value-added tax. If generics or biosimilars were available, the calculation was based on the minimum registered prices.

RESULTS

Netakimab is the least costly in treating psoriasis vulgaris compared to other biologics and small molecules with comparable or superior efficacy assessed using PASI 75 and PASI 90. To achieve costs equal to those required for the treatment of psoriasis vulgaris with netakimab for 2 years, it is necessary to reduce the cost of competitors by 30—74%, which corresponds to the provision of 0.4 to 2.8 additional packages free of charge for each package purchased.

CONCLUSION

Expanding the use of netakimab for treating adult patients with moderate to severe psoriasis vulgaris will reduce the cost of the Russian health care system, with comparable or higher clinical efficacy compared to other genetically engineered biological drugs and small molecules. Netakimab can be considered the drug of choice.